Photo: Jeff Lagasse/Healthcare Finance News
Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter sent to the drugmakers this week from the Health Resources and Services Administration.
The HRSA maintained that the drug manufacturers in question – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics – placed restrictions on the 340B program for hospitals that dispense drugs through contract pharmacies, and these restrictions resulted in overcharges, which are in direct violation of the statute.
Various actions from the manufacturers limited beneficiaries access to discounted drugs available through the 340B program, HRSA said. Some, for instance, stopped providing the 340B ceiling price on products sold to covered entities and dispensed through contract pharmacies. Others limited sales by requiring specific
Latinos for Washington Ally Comments on Governor s Stance Against Border Migrants | KCII Radio
kciiradio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kciiradio.com Daily Mail and Mail on Sunday newspapers.
Give her a medal: In praise of Dr Nancy Messonnier
nydailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nydailynews.com Daily Mail and Mail on Sunday newspapers.